文献速递创伤与烧伤心脑血管急症

人脂肪源性干细胞治疗在体外和体内创伤性脑损伤模型中调节细胞保护作用

Human adipose-derived stem cell treatment modulates cellular protection in both in vitro and in vivo traumatic brain injury models.
PubMed 文献 · J Trauma Acute Care Surg · 2018-01-01
一句话结论在体外创伤性脑损伤模型中人脂肪源性干细胞条件培养基减少细胞死亡并改善线粒体功能,在大鼠创伤性脑损伤模型中静脉注射人脂肪源性干细胞降低TNF-α和β-APP表达,但功能恢复无差异。

本研究通过体外和体内两种方法探讨脂肪源性干细胞(ASC)治疗对创伤性脑损伤(TBI)细胞和功能恢复的影响。体外实验用SH-SY5Y神经母细胞瘤细胞划痕模拟TBI,ASC条件培养基减少细胞死亡、增加细胞活力和线粒体功能、降低IL-1β。体内实验将Sprague-Dawley大鼠随机分为静脉注射人源ASC组、静脉注射生理盐水组和假手术组,伤后3小时内给药;ASC组功能恢复与TBI组无差异,但TNF-α和β-APP表达降低。作者认为ASC治疗可能有助于TBI后神经细胞的细胞保护和恢复。

要点

  • 体外划痕TBI模型中,ASC条件培养基组细胞死亡比值1.21 ± 0.066 vs 对照组1.01 ± 0.056(p = 0.017),细胞死亡减少。
  • 体外模型中ASC条件培养基组细胞活力比值0.86 ± 0.009 vs 对照组1.09 ± 0.01(p = 0.0001),细胞活力增加。
  • 体内大鼠TBI模型中,静脉注射人源ASC组与TBI组功能恢复(加速Rotarod法)无差异。
  • 体内伤后3天,ASC组TNF-α表达比值0.47 ± 0.01 vs TBI组0.67 ± 0.04(p < 0.01),β-APP荧光比值0.43 ± 0.05 vs 0.69 ± 0.03(p < 0.01),均降低。

适用人群与场景

  • 体外:培养的SH-SY5Y神经母细胞瘤细胞,划痕法模拟TBI。
  • 体内:Sprague-Dawley大鼠,采用额部闭合性颅脑损伤模型。

处置流程与药物剂量

  • 体内模型:动物在伤后3小时内随机接受静脉注射人源ASC或静脉注射生理盐水,并与假手术组比较。
  • 功能恢复采用加速Rotarod法评估;伤后第3天取脑组织,用酶联免疫吸附法测TNF-α,用免疫组化染色测β-APP。

研究设计与关键结果

  • 研究类型:体外细胞实验联合体内大鼠实验。
  • 体外:ASC条件培养基组细胞死亡比值1.21 ± 0.066 vs 对照组1.01 ± 0.056(p = 0.017),细胞活力比值0.86 ± 0.009 vs 对照组1.09 ± 0.01(p = 0.0001),线粒体功能为对照组的78 ± 6% vs 68 ± 3%,IL-1β水平显著降低。
  • 体内:与单纯TBI组相比,ASC治疗组功能恢复无差异,TNF-α表达比值0.47 ± 0.01 vs 0.67 ± 0.04(p < 0.01),β-APP荧光比值0.43 ± 0.05 vs 0.69 ± 0.03(p < 0.01),均降低。

证据类型、等级与局限

  • 证据类型:体外细胞实验和体内动物实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些数据提示ASC治疗可能有助于TBI后神经细胞的细胞保护和恢复。
  • 原文未据此给出临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Traumatic brain injury (TBI) is a common cause of morbidity and mortality in the civilian population. The purpose of this study was to examine the effect(s) of adipose-derived stem cell (ASC) treatment on cellular and functional recovery in TBI via both in vitro and in vivo methods.

METHODS: Cultured neuroblastoma cells, SH-SY5Y, were scratched to mimic TBI in an in vitro model. The effect of ASC-conditioned medium (CM) on cell death, mitochondrial function, and expression of inflammatory cytokines (tumor necrosis factor α [TNF-α], interleukin 1β [IL-1β], and IL-6), as well as apoptosis marker FAS, was measured. In our in vivo model, Sprague-Dawley rats underwent TBI via a frontal, closed-head injury model. Animals randomly received either intravenous human-derived ASCs or intravenous saline within 3 hours of injury and were compared with a sham group. Functional recovery was evaluated via accelerating Rotarod method. On post-TBI Day 3, brain tissue was harvested and assessed for cellular damage via enzyme-linked immunosorbent assay for TNF-α, as well as immunohistochemical staining for β-amyloid precursor protein (β-APP).

RESULTS: Our in vitro data show that ASC treatment imparted reduced cell death (ratio to control: 1.21 ± 0.066 vs. 1.01 ± 0.056, p = 0.017), increased cell viability (ratio to control: 0.86 ± 0.009 vs. 1.09 ± 0.01, p = 0.0001), increased mitochondrial function (percentage of control: 78 ± 6% vs. 68 ± 3%), and significantly decreased levels of inflammatory cytokine IL-1β. In our in vivo study, compared with TBI alone, ASC-treated animals showed no difference in functional recovery, lower levels of expressed TNF-α (ratio to total protein, 0.47 ± 0.01 vs. 0.67 ± 0.04; p < 0.01), and lower levels of β-amyloid precursor protein (fluorescence ratio, 0.43 ± 0.05 vs. 0.69 ± 0.03; p < 0.01).

CONCLUSIONS: Adipose-derived stem cell treatment results in improved cell survival, decreased inflammatory marker release, and decreased evidence of neural injury. No difference in functional recovery was seen. These data suggest the potential for ASC treatment to aid in cellular protection and recovery in neural cells following TBI.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Kappy NS, Chang S, Harris WM, et al. Human adipose-derived stem cell treatment modulates cellular protection in both in vitro and in vivo traumatic brain injury models. J Trauma Acute Care Surg. 2018. PMID: 29251705. doi:10.1097/TA.0000000000001770

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。